TOPARP-B: A Randomised Phase 2 Trial Evaluating Two Doses of Olaparib Against Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
Loading...
Embargo End Date
Authors
Hall, E
De Bono, J
Porta, N
Miranda, S
Flohr, P
Ferreira, A
Riisnaes, R
Chatfield, P
Carreira, S
Yuan, W
Tunariu, N
Espinasse, A
Crespo, M
Nava Rodrigues, D
Gurel, B
Clarke, M
Curcean, A
Pereira, AR
Fowler, G
Rescigno, P
Ebbs, B
Bertan, C
Seed, G
Figueiredo, I
De Bono, J
Porta, N
Miranda, S
Flohr, P
Ferreira, A
Riisnaes, R
Chatfield, P
Carreira, S
Yuan, W
Tunariu, N
Espinasse, A
Crespo, M
Nava Rodrigues, D
Gurel, B
Clarke, M
Curcean, A
Pereira, AR
Fowler, G
Rescigno, P
Ebbs, B
Bertan, C
Seed, G
Figueiredo, I
Document Type
Journal Article
Date
Date Accepted
2019-10-04
Abstract
Citation
The Lancet Oncology
DOI
Source Title
Publisher
Elsevier
ISSN
1213-9432
eISSN
Collections
Research Team
Cancer Biomarkers
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Prostate Cancer Targeted Therapy Group
Clinical Trials & Statistics Unit
ICR-CTSU Urology and Head and Neck Trials Team
Prostate Cancer Targeted Therapy Group